Literature DB >> 2174962

Expression of the full-length products of the human papillomavirus type 6b (HPV-6b) and HPV-11 L2 open reading frames by recombinant baculovirus, and antigenic comparisons with HPV-11 whole virus particles.

R C Rose1, W Bonnez, D G Strike, R C Reichman.   

Abstract

The L2 open reading frames (ORFs) of human papillomavirus (HPV) types 6b and 11 were expressed as full-length non-fusion proteins in Spodoptera frugiperda (Sf-9) cells using recombinant baculovirus. Both proteins were detected on Western blots as immunoreactive bands which migrated with apparent Mrs of 76K and 78K, respectively, and contained both cross-reactive and type-specific epitopes, as determined by polyclonal antisera directed against defined subregions of the HPV-6b and HPV-11 L2 ORFs. In addition, the minor capsid protein of HPV-11 particles co-migrates with the HPV-11 L2 ORF product and is immunoreactive with HPV-11 L2-specific antisera. These observations indicate that the anomalous electrophoretic mobilities of papillomavirus L2 ORF proteins can be explained without invoking post-transcriptional processing events and that the minor capsid protein of HPV-11 is antigenically and biophysically related to the HPV-11 L2 ORF product.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2174962     DOI: 10.1099/0022-1317-71-11-2725

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  12 in total

1.  Characterization of an IL-12 p40/p35 Truncated Fusion Protein That can Inhibit the Action of IL-12.

Authors:  Denise Skrombolas; Isabel Wylie; Shivana Maharaj; John G Frelinger
Journal:  J Interferon Cytokine Res       Date:  2015-05-04       Impact factor: 2.607

2.  Preparation and properties of a papillomavirus infectious intermediate and its utility for neutralization studies.

Authors:  Joshua W Wang; Subhashini Jagu; Kihyuck Kwak; Chenguang Wang; Shiwen Peng; Reinhard Kirnbauer; Richard B S Roden
Journal:  Virology       Date:  2013-12-20       Impact factor: 3.616

3.  Development of an Interleukin-12 Fusion Protein That Is Activated by Cleavage with Matrix Metalloproteinase 9.

Authors:  Denise Skrombolas; Mark Sullivan; John G Frelinger
Journal:  J Interferon Cytokine Res       Date:  2019-03-08       Impact factor: 2.607

4.  Two E2 binding sites (E2BS) alone or one E2BS plus an A/T-rich region are minimal requirements for the replication of the human papillomavirus type 11 origin.

Authors:  J Z Lu; Y N Sun; R C Rose; W Bonnez; D J McCance
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

5.  Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women.

Authors:  R P Viscidi; K L Kotloff; B Clayman; K Russ; S Shapiro; K V Shah
Journal:  Clin Diagn Lab Immunol       Date:  1997-03

6.  Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases.

Authors:  John Puskas; Denise Skrombolas; Abigail Sedlacek; Edith Lord; Mark Sullivan; John Frelinger
Journal:  Immunology       Date:  2011-03-23       Impact factor: 7.397

7.  Oral immunogenicity of human papillomavirus-like particles expressed in potato.

Authors:  Heribert Warzecha; Hugh S Mason; Christopher Lane; Anders Tryggvesson; Edward Rybicki; Anna-Lise Williamson; John D Clements; Robert C Rose
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

Review 8.  L2, the minor capsid protein of papillomavirus.

Authors:  Joshua W Wang; Richard B S Roden
Journal:  Virology       Date:  2013-05-17       Impact factor: 3.616

9.  Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles.

Authors:  R C Rose; W Bonnez; R C Reichman; R L Garcea
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

10.  Antigenic presentation of heterologous epitopes engineered into the outer surface-exposed helix 4 loop region of human papillomavirus L1 capsomeres.

Authors:  Yoshihiko Murata; Paula M Lightfoote; Robert C Rose; Edward E Walsh
Journal:  Virol J       Date:  2009-06-18       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.